Retatrutide Research

Retatrutide 20 mg is supplied by Healthy Peps as a lyophilized research peptide in a single sealed vial, shipped from Canada with batch documentation and an available Certificate of Analysis.

Physicochemical Reference Data

Mechanism & Research Context

Retatrutide is a synthetic peptide engineered as an unbalanced triple agonist at the GIP, GLP-1 and glucagon receptors. Published receptor pharmacology describes single-molecule co-activation of all three receptors, which is the reason it appears repeatedly in the literature on incretin and glucagon receptor co-agonism: the research question is whether adding glucagon receptor activity to the incretin effect alters energy-expenditure signalling in ways a dual GIP/GLP-1 agonist does not.

For laboratory work, retatrutide is used to study receptor-mediated G-protein signalling, cAMP accumulation and downstream metabolic pathway activation in cell-based assay systems. The peptide is also used as a comparator compound when researchers want a three-receptor agonist profile alongside dual-agonist or single-agonist reference standards in the same assay plate.

The most cited clinical dataset is the phase 2 obesity trial reported by Jastreboff and colleagues in the New England Journal of Medicine (2023), which examined dose-dependent body-weight changes over 48 weeks. That study is frequently used in the literature as a reference point for the potency of triple-receptor co-agonism relative to established single and dual agonists.

Healthy Peps supplies the 20 mg format because extended in vitro assay series typically require repeat preparations from one documented batch; a single larger vial keeps the same batch number and purity result behind an entire experimental series, which is the point of batch-specific documentation.

How It Compares to Related Peptides

Compared with dual GIP/GLP-1 agonists, retatrutide adds a third receptor axis, which is why it is used in research designs that specifically measure glucagon receptor contribution. Compared with CJC-1295 No DAC or ipamorelin on this catalogue — which act on the GH/ghrelin axis — retatrutide belongs to a completely separate receptor family, so it is not a substitute in a growth-hormone research protocol.

Reconstitution, Stability & Handling

Reconstitute in a suitable laboratory diluent such as bacteriostatic water; add diluent down the vial wall and swirl gently rather than vortexing, since mechanical shear can aggregate peptides. Reconstituted material is best stored refrigerated and used within the working period set by your own protocol, and should be aliquoted if repeated freeze-thaw cycles are unavoidable. Solutions should remain clear; a cloudy or precipitate-containing preparation should not be used.

Selected Reading & Research Notes

• Jastreboff et al. (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Phase 2 clinical research. The investigational trial material is not evidence of the identity, safety or efficacy of a catalogue product.

Frequently Asked Questions